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During the last two decades incidences of fungal infections dramatically increased and
the often accompanying failure of available antifungal therapies represents a substantial
clinical problem. The urgent need for novel antimycotics called particular attention to the
study of natural products. The genus Hypericum includes many species that are used
in the traditional medicine to treat pathological states like inflammations and infections
caused by fungi. However, despite the diffused use of Hypericum-based products the
antifungal potential of the genus is still poorly investigated. In this study five Hypericum
species autochthonous of Central and Eastern Europe were evaluated regarding their
polyphenolic content, their toxicological safety and their antifungal potential against a
broad panel of clinical fungal isolates. LC-MS analysis led to the identification and
quantification of 52 compounds, revealing that Hypericum extracts are rich sources
of flavonols, benzoates and cinnamates, and of flavan-3-ols. An in-depth screen of
the biological activity of crude extracts clearly unveiled H. hircinum subsp. majus as a
promising candidate species for the search of novel antifungals. H. hircinum is diffused
in the Mediterranean basin from Spain to Turkey where it is traditionally used to prepare a
herbal tea indicated for the treatment of respiratory tract disorders, several of which are
caused by fungi. Noteworthy, the infusion of H. hircinum subsp. majus excreted broad
antifungal activity against Penicillium, Aspergillus and non-albicans Candida isolates
comprising strains both sensitive and resistant to fluconazole. Additionally, it showed
no cytotoxicity on human cells and the chemical characterization of the H. hircinum
subsp. majus infusion revealed high amounts of the metabolite hyperoside. These results
scientifically support the traditional use of H. hircinum extracts for the treatment of
respiratory tract infections and suggest the presence of exploitable antifungal principles
for further investigations aimed at developing novel antifungal therapies.
Keywords: Hypericum, antifungal, Candida, cytotoxicity, LC-MS, phenolic compounds
Abbreviations: CFU, colony forming units; GM, geometric mean; LC-MS, liquid chromatography-mass spectrometry;
MIC, minimal inhibitory concentration.
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INTRODUCTION
The rising incidence of fungal infections is an emerging serious
health problem, especially in cases of immune compromised
patients caused either by diseases like AIDS, or by cancer
therapies and prolonged antibiotic treatments (Lass-Flörl, 2009;
Weil et al., 2017). Estimates of global mortality rates suggest that
fungi are responsible for more deaths than either tuberculosis
or malaria (Brown et al., 2012). Millions more suffer from
severe illness caused by chronic or allergic fungal infections.
Candidiasis is the most prevalent fungal disease worldwide
difficult and extremely costly to treat (World Health Organization
[WHO], 2014). The available antifungal drugs like polyenes,
pyrimidines, azoles, and echinocandins often provoke significant
toxicity including fever, nausea and vomiting, dose-limiting
nephrotoxicity, liver toxicity, and controversial interactions with
co-administered drugs (Dismukes, 2000; Zager, 2000). Another
crucial problem is represented by the increasing rate of drug
resistance that invalidates the clinical treatments. The alarming
gap in the anti-fungal pipeline makes the discovery of new
active compounds a priority for the scientific community. The
strong request of new classes of compounds has renewed
the interest in the screening of natural products (Abreu
et al., 2012; Atanasov et al., 2016). Especially, ethnobotany
represents an important guide in the search of novel antifungal
agents. Due to their ability to synthesize a limitless variety
of chemical structures, plants have represented a source of
bioactive remedies for centuries (Arif et al., 2009). Despite of
this, it is estimated that only a small proportion of plants
are used by humans. Therefore, bioactivity screening programs
and research on new plant-derived compounds are of prime
importance for the search of novel leads. Plants belonging
to the genus Hypericum, are characteristic components of the
European flora. In particular, Europe and the Mediterranean
basin represent a hot spot of diversity for Hypericum species
(Nürk and Crockett, 2011). The best characterized species is
H. perforatum L., which was already described by Hippocrates
as a remedy against possession in the Ancient Greece (Dugoua
et al., 2006). During the centuries it has been used for
the treatment of various pathological states, like neurological
disorders, wounds, inflammations, and infections. The use
of H. perforatum extracts is so popular that this species is
considered the most important medicinal plant of the 20th
century (Gurib-Fakim, 2006). The German Commission E
approved its usage for several indications, including treatment
and post-therapy of acute and contused injuries, myalgia and
first-degree burns as well as dyspeptic complaints (Arsic et al.,
2010). In the Balkan Countries it is considered as one of
the oldest remedies and in the Serbian folk medicine it is
indicated for the treatment of cuts, burns, hemorrhoids and
also as an antiseptic, for liver and stomach complaints, diarrhea,
and gastric ulcers. Its sale represents a huge part of the
overall herbal market (Crockett et al., 2011), exceeding $570
million/annum worldwide (Ayan et al., 2006). Regarding its
antifungal potential, inhibitory properties against Candida spp.,
(Tocci et al., 2013) and fungal plant pathogens (Crockett et al.,
2011) have been reported. Nevertheless, a growing number of
scientific evidences underlines the importance to investigate
other Hypericum species that might exert a more promising
antifungal activity (Radulovic´ et al., 2007; Stojanovic et al., 2013).
In this regard the species H. carinatum, H. myrianthum, H.
linoides (Barros et al., 2013), H. garciae (Tocci et al., 2018a) have
been shown to have the potential to inhibit the growth of Candida
spp. Cryptococcus neoformans and Rhodotorula mucilaginosa
growth.
In Central and Eastern Europe several different Hypericum
species co-occur and the area is considered a significant source of
plant material for the market of herbal products (Raclariu et al.,
2017).
Amongst others, H. maculatum Crantz subsp. maculatum,
H. hircinum L. s. lat., H. hirsutum L., and H. montanum
L., as plants used to treat wounds, skin inflammations and
burns (Menkovic et al., 2011), as well as infections of the
respiratory (Sagratini et al., 2008) and urinary tract (Saric´-
Kundalic´ et al., 2010). These pathologies are often caused
by fungi, with Candida as the main causative agent and by
dermatophytes in the case of external infections (Borgers et al.,
2005; Johnson, 2012; Ritchie and Eltahawy, 2014). To screen for
new candidates suitable for the development of novel antimycotic
solutions, we studied extracts deriving from the aerial parts
of several Hypericum taxa (H. perforatum L., H. maculatum
Crantz subsp. maculatum, H. hircinum L. s.lat., H. hirsutum L.,
and H. montanum L.) with respect to their chemical profile,
their antifungal activity against a broad panel of clinical fungal
isolates of the human gut and their toxicological safety on
human skin fibroblasts and peripheral blood mononuclear cells
(PBMCs).
MATERIALS AND METHODS
Plant Material
Samples of H. hirsutum subsp. hirsutum, H. hircinum subsp.
majus, H. maculatum, H. montanum, and H. perforatum
have been collected during spring-summer of 2015 in the
Alpine region (Northern-Eastern Italy). Species were identified
according to the most recent Flora of Italy (Pignatti, 1982,
2017), nomenclature follows Bartolucci et al. (2018) and
type specimens were deposited in the Department of Food
Quality and Nutrition at the Fondazione Edmund Mach
in San Michele all’Adige, Trento, Italy (Reference number:
NT0001 H. perforatum, NT0002 H. montanum, NT0003
H. maculatum, NT0004 H. hirsutum, NT0005 H. hircinum subsp.
majus).
Preparation of Crude Plant Extracts
For each species, 500 mg of dried plant biomass, represented
by stems and leaves, were powdered by grinding and extracted
in the dark with methanol (drug/solvent ratio = 1:20 w/v) by
maceration (3 × 24 h). H. hircinum subsp. majus was also
subjected to extractions with boiling water (100◦C) for 20 min,
and ethanol 80% by maceration for 24 h. The obtained extracts
were evaporated to dryness, weighed and stored at −20◦C until
analysis.
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Preparation of Samples for Chemical
Analysis
Prior to analysis methanolic extracts were resuspended in
50% methanol/water and filtered using sterile (0.2 µm) PTFE
filters.
LC-MS Analysis
Analysis of phenolic metabolites was performed using a
Waters Acquity UPLC system (Milford, MA, United States)
which consists of a binary pump, an online vacuum degasser,
an autosampler and a column compartment as previously
described (Vrhovsek et al., 2012). Phenolic compounds were
separated at a temperature of 40◦C on a Waters Acquity
HSS T3 column 1.8 µm, 150 mm × 2.1 mm (Milford,
MA, United States). The mobile phase was composed of
component A (0.1% formic acid in water) and component B
(0.1% formic acid in acetonitrile). Acetonitrile was of LC-MS
grade and was purchased from Sigma–Aldrich (St. Louis, MO,
United States). Pure standards of hypericin from Hypericum
perforatum ∼95% (HPLC), hyperoside and hyperforin were
purchased from Sigma-Aldrich (St. Louis, MO, United States).
Milli-Q water was used for the chromatography. The flow
was set to 0.4 mL/min, and the gradient profile was: 0 min,
5% B; from 0 to 3 min, linear gradient to 20% B; from
3 to 4.3 min, isocratic 20% B; from 4.3 to 9 min, linear
gradient to 45% B; from 9 to 11 min, linear gradient to
100% B; from 11 to 13 min, wash at 100% B; from 13.01
to 15 min, the re-equilibrated to the initial conditions of
5% B. Analysis of hypericin, hyperforin and hyperoside was
performed using the same Waters Acquity UPLC system
(Milford, MA, United States) and conditions, by means of a
different gradient. The gradient profile in this case was: 0 min,
10% B; from 0 to 4,5 min, linear gradient to 100% B; from
4,5 to 12 min, isocratic 100% B; finally the column was re-
equilibrated to the initial conditions of 10% B for 4 min.
MRM transitions for hypericin, hyperforin and hyperoside are
reported in Supplementary Table S1. Each sample was analyzed
in triplicate. Samples were kept at 6◦C during the analysis. Mass
spectrometry detection for both methods was performed on a
Waters Xevo TQMS (Milford, MA, United States) instrument
equipped with an electrospray (ESI) source. Capillary voltage
was 3.5 kV in positive mode and −2.5 kV in negative mode;
the source was kept at 150◦C; the desolvation temperature
was 500◦C; cone gas flow, 50 L/h; and desolvation gas flow,
800 L/h. Further MS parameters are reported in Vrhovsek et al.,
2012.
Data Analysis
Quantification was done using Waters MassLynx 4.1 and
TargetLynx software.
Microorganisms and Media
For antifungal susceptibility testing, the reference strain
C. albicans ATCC MYA-2876 from the American Type Culture
Collection (ATCC), Rockville, MD, United States was used. The
human gut clinical isolates, C. albicans YN7, C. parapsilosis YB1,
C. parapsilosis YB3 (Di Paola et al., unpublished), C. albicans
YHS254, C. albicans YHS89, C. lusitaniae YHS217, C. lusitaniae
YHS72, C. parapsilosis YHS133, C. parapsilosis YHS312,
C. parapsilosis YHS301, Aspergillus glaucus YHS165, Penicillium
paneum YHS245 (Strati et al., 2016), C. glabrata MFB004,
C. tropicalis MFB035-1, C. tropicalis RTT037-3 (Strati et al.,
unpublished) were tested for their susceptibility against the
applied drugs. All strains were grown on Sabouraud agarized
medium for 48 h at 30◦C before testing.
Antifungal Susceptibility Testing
Candida strains were tested for their susceptibility to
Hypericum spp. extracts (7 dilution series, ranging from
500 to 8 µg/ml) following the European Committee for
Antimicrobial Susceptibility Testing protocol (EUCAST
DEFINITIVE DOCUMENT EDef 7.2 Revision; European
Committee for Antimicrobial Susceptibility Testing, 2012).
Briefly, cells were grown in RPMI1640 medium supplied with
2.0% glucose, counted and inoculated at a concentration
of 1–5 × 105 CFU/ml. MIC50 and MIC90 values were
determined at 530 nm using a spectrophotometer, as the
lowest concentration of the drug that resulted in ≥50% and
≥90% inhibition of growth relative to the growth control after
48 h incubation.
PBMC Isolation
Peripheral blood mononuclear cells were obtained from
buffy coat of healthy donors (as approved by the Ethical
Committee of the local health centre, Azienda Provinciale
per I Servizi Sanitari, Provincia Autonoma di Trento)
within 4 h from sample collection. PBMC isolation was
performed using Lympholite (CEDARLANE) density gradient
(1.077 g/liter, pH 6,9), according to manufacturer’s instructions,
and incubated in complete nutrient RPMI 1640 medium
(Euroclone) supplemented with glutamine (2 mol/L), 10%
fetal calf serum (FCS) and antibiotics (10000 U/ml Penicillin,
10000 µg/ml Streptomycin) (Biological Industries), at 37◦C and
5% CO2.
Cytotoxicity Assay
The cytotoxicity of H. hircinum subsp. majus infusion,
methanolic and hydro-alcoholic extracts was tested using the
WST-8 (4-[3-(2-methoxy-4-nitrophenyl)-2-(4-nitrophenyl)-2H-
5-tetrazolio]-1,3-benzene disulfonate sodium salt) conversion
assay. The cytotoxicity of the extracts was evaluated on
two normal cell lines, namely PBMC and human foreskin
fibroblast Hs27. Cells were seeded in 96-well culture plates
at concentration of 5000 cells/well and incubated for 24 h
before treatment with H. hircinum subsp. majus extracts.
Plant extracts were diluted in DMSO and added to a final
concentration of 500 µg/ml (final volume of DMSO 0,5%
v/v). To measure the cytotoxic effects 10 µl of Cell Counting
Kit-8 (Sigma-Aldrich) (containing the WST-8 solution) were
added to each well and incubated for 2–4 h for fibroblasts and
PBMCs, respectively, at 37◦C before reading the absorbance at
450 nm.
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TABLE 1 | Analysis of phenolic compounds in the crude extracts of Hypericum species.
H. hirc majus H. hirs H. mac H. mont H. perf
µg/g extract
Benzoates and cinnamates 427,04 ± 47,1 45,9 ± 3,65 243,22 ± 1,14 390,72 ± 6,17 112,6 ± 10,5
2,6-di-OH-benzoic acid nd∗ nd∗ nd∗ nd∗ nd∗
3,5-dihydroxybenzoic acid 1,78 ± 0,013 1,98 ± 0,012 1,47 ± 0,013 0,98 ± 0,009 0,96 ± 0,016
Caffeic acid nd∗ nd∗ nd∗ nd∗ nd∗
Cinnamic acid nd∗ nd∗ nd∗ nd∗ nd∗
Ellagic acid 5,83 ± 0,073 3,29 ± 0,088 7,22 ± 0,114 6,25 ± 0,10 2,18 ± 0,054
Ferulic acid 0,06 ± 0,003 0,38 ± 0,003 0,54 ± 0,012 nd∗ 0,26 ± 0,006
Gallic acid 0,70 ± 0,028 1,07 ± 0,008 0,51 ± 0,013 0,73 ± 0,032 0,42 ± 0,0013
p-coumaric acid 0,08 ± 0,001 0,6 ± 0,019 0,26 ± 0,009 0,25 ± 0,002 0,23 ± 0,007
p-OH-benzoic acid nd∗ nd∗ nd∗ nd∗ nd∗
Vanillic acid nd∗ nd∗ nd∗ nd∗ nd∗
Chlorogenic acid 323,03 ± 4,946 8,51 ± 0,450 nd∗ nd∗ 18,92 ± 0,949
Cryptochlorogenic acid 0,58 ± 0,009 0,12 ± 0,007 1,32 ± 0,048 4,44 ± 0,025 0,72 ± 0,01
Neochlorogenic acid 95,07 ± 0,194 29,95 ± 0,032 231,90 ± 0,112 378,07 ± 0,449 88,91 ± 0,204
Flavonols 9393,64 ± 50,3 7470,05 ± 28,01 6555,52 ± 30,21 5284,31 ± 13,25 7189,19 ± 47,26
Hyperoside 9306 ± 385 7430 ± 211 6240 ± 488 4940 ± 66,3 6880 ± 469
Quercetin 2,28 ± 0,043 9,67 ± 0,063 45,44 ± 0,159 14,35 ± 0,085 5,13 ± 0,011
Quercetin-3-arabinoside nd∗ 0,19 ± 0,005 32,40 ± 0,099 23,19 ± 0,047 132,86 ± 1,522
Quercetin-3-glucoside 43,56 ± 0,536 18,12 ± 0,529 226,89 ± 1,948 235,33 ± 1,712 14,28 ± 0,479
Quercetin-3-glucuronide 28,77 ± 0,212 nd∗ nd∗ nd∗ 2,54 ± 0,02
Quercetin-3-sulfate 11,91 ± 0,026 2,22 ± 0,018 4,64 ± 0,024 0,69 ± 0,004 34,82 ± 0,024
Rutin nd∗ 2,47 ± 0,031 3,19 ± 0,015 0,86 ± 0,006 118,89 ± 0,197
Kaempferol 0,025 ± 0,001 1,73 ± 0,007 0,43 ± 0,005 0,11 ± 0,001 0,19 ± 0,001
Kaempferol-3-glucuronide 0,48 ± 0,0151 nd∗ nd∗ nd∗ 0,05 ± 0,001
Kaempferol -3-glucoside 0,38 ± 0,012 2,38 ± 0,071 2,16 ± 0,038 1,18 ± 0,031 0,33 ± 0,009
Syringetin-3-glucoside nd∗ nd∗ nd∗ nd∗ nd∗
Iso-rhamnetin nd∗ nd∗ 0,13 ± 0,003 nd∗ nd∗
Iso-rhamnetine-3-glucoside nd∗ 0,08 ± 0,004 nd∗ nd∗ nd∗
Myricetin 0,23 ± 0,004 3,19 ± 0,014 0,24 ± 0,003 0,29 ± 0,004 0,10 ± 0,002
Flavones 0,65 ± 0,036 2,215 ± 0,016 1,175 ± 0,006 3,035 ± 0,014 0,45 ± 0,010
Luteolin trace 1,93 ± 0,011 0,79 ± 0,004 2,52 ± 0,009 0,22 ± 0,006
Luteolin 7-O-glucoside 0,65 ± 0,036 0,28 ± 0,005 0,38 ± 0,002 0,51 ± 0,005 0,18 ± 0,004
Flavanones 0,44 ± 0,009 1,43 ± 0,031 0,58 ± 0,018 2,3 ± 0,009 0,82 ± 0,016
sNaringenin 0,05 ± 0,004 0,18 ± 0,006 nd∗ 0,07 ± 0,002 0,10 ± 0,004
Naringenin-7-glucoside 0,39 ± 0,005 1,25 ± 0,025 0,58 ± 0,018 2,23 ± 0,007 0,72 ± 0,012
Chalcones 0,11 ± 0,006 0,42 ± 0,005 0,32 ± 0,008 nd∗ 0,31 ± 0,005
Phlorizin 0,11 ± 0,006 0,42 ± 0,005 0,32 ± 0,008 nd∗ 0,31 ± 0,005
Coumarins 0,23 ± 0,0032 0,07 ± 0,002 0,14 ± 0,004 0,55 ± 0,005 0,22 ± 0,002
Esculin 0,23 ± 0,0032 0,07 ± 0,002 0,14 ± 0,004 0,55 ± 0,005 0,22 ± 0,002
Flavan-3-ols 53,12 ± 1,24 74,12 ± 3,12 100,09 ± 4,81 58,28 ± 1,53 59,47 ± 2,47
Catechin 21,94 ± 0,609 5,25 ± 0,034 3,68 ± 0,114 1,79 ± 0,048 4,21 ± 0,161
Epicatechin 19,28 ± 0,212 40,21 ± 0,258 68,52 ± 0,029 53,61 ± 0,166 43,76 ± 0,17
Epigallocatechin 3,31 ± 0,030 0,42 ± 0,014 0,52 ± 0,008 1,44 ± 0,031 0,82 ± 0,025
Gallocatechin 2,21 ± 0,032 nd∗ nd∗ nd∗ nd∗
Procyanidin B1 1,37 ± 0,007 0,94 ± 0,025 0,89 ± 0,018 nd∗ 0,42 ± 0,005
Procyanidin B2 5,01 ± 0,091 27,3 ± 0,521 26,48 ± 0,770 1,44 ± 0,287 10,26 ± 0,111
Stilbenoids 0,06 ± 0,001 0,91 ± 0,015 2,24 ± 0,009 0,99 ± 0,008 3,32 ± 0,052
cis-piceid 0,06 ± 0,001 0,91 ± 0,015 2,24 ± 0,009 0,99 ± 0,008 3,32 ± 0,052
Phloroglucinols nd∗ nd∗ nd∗ 20 ± 1,91 8050 ± 565
Hyperforin nd∗ nd∗ nd∗ 20 ± 1,91 8050 ± 565
Naphtodianthrones nd∗ 30 ± 1,79 20 ± 1,71 40 ± 2,67 150 ± 25,1
Hypericin nd∗ 30 ± 1,79 20 ± 1,71 40 ± 2,67 150 ± 25,1
H. hirs majus, H. hircinum subsp. majus; H. hirs, H. hirsutum; H. mac, H. maculatum; H. mon, H. montanum; H. perf, H. perforatum. ∗nd, not detected.
Frontiers in Pharmacology | www.frontiersin.org 4 April 2018 | Volume 9 | Article 382
fphar-09-00382 April 20, 2018 Time: 12:10 # 5
Tocci et al. Antimycotic Hypericum Herbal Extracts
The results were analyzed by Student’s t-test. The data are
expressed as the percentage of viability and standard error of the
mean.
Microscopy
To estimate the impact of plant extracts on cell morphology and
health, cultures were visualized and recorded using an inverted
microscope Motic AE31 equipped with a camera Moticam 580
5.0 MP.
RESULTS
Extract Composition
The extracts have been chemically characterized by the
identification and quantification of 52 low molecular weight
polyphenols belonging to the classes: flavonols, benzoates
and cinnamates, chalcones, flavan-3-ols, flavones, stilbens,
coumarins, phloroglucinols, and naphtodianthrones (Table 1).
LC-MS analysis revealed that species were characterized by
different content of the detected metabolites, yet in all of the
extracts, quercetin derivatives represented the most prevalent
group of compounds.
Quercetin and quercetin glycosides ranged from 5,21 mg/g
in H. montanum to 9,4 mg/g in H. hircinum subsp. majus,
with hyperoside being the major compounds in the extracts
representing the 45,48% of the detected compounds in
H. perforatum and more than the 99% in the other Hypericum
species. Quercetin-3-glucoside was abundant in H. maculatum
and in H. montanum, while quercetin 3-rhamnoside was highly
present in H. perforatum (132,9 µg/g). Quercetin-3-glucuronide
only occurred in H. hircinum subsp. majus (28,8 µg/g) and
in H. perforatum (10-fold less concentrated). Chlorogenic
acid derivatives (chlorogenic acid, neochlorogenic acid, and
cryptochlorogenic acid) ranged from 38 µg/g for H. hirsutum
and H. perforatum to 456,7 µg/g in H. hircinum subsp. majus.
Also the flavan-3-ols were relatively abundant ranging from
53,12 µg/g in H. hircinum subsp. majus to 100,12 µg/g in
H. maculatum, with epicatechin being the principal compound
of this class (from 19 µg/g in H. hircinum subsp. majus up to
68,5 µg/g in H. maculatum).
Antifungal Activity of Hypericum Crude
Extracts
Hypericum extracts were screened against a panel of clinical
Candida isolates (Table 2 and Supplementary Table S2) and the
results are hereafter given as GM of MIC values. The screening
unveiled that H. hircinum subsp. majus crude methanolic extract
had a strong anti-Candida activity against all tested fungal
strains, with inhibition properties against C. parapsilosis (MIC50
53,5 µg/ml) in the same magnitude of fluconazole (MIC50
22,63 µg/ml).
All extracts exerted antifungal properties against C. albicans
and C. lusitaniae while only H. hircinum subsp. majus was also
active against C. tropicalis and C. glabrata (MIC50 353,55 and
16 µg/ml, respectively).
Also, with respect to the to the MIC90 values, H. hircinum
subsp.majus extract showed higher inhibitory properties than the
other tested extracts (Supplementary Table S2).
TABLE 2 | Antifungal activity of Hypericum species.
Species (strain no.) H. hircinum H. maculatum H. montanum H. perforatum H. hirsutum Fluconazole
MIC50 Range MIC50 Range MIC50 Range MIC50 Range MIC50 Range MIC50 Range
C. albicans (2) 63,25 32–125 250 250 500 500 353,3 250–500 500 500 0,35 0,125–1
C. parapsilosis (2) 32 32 500 500 >500 >500 >125 125–500 >500 500 48 32–64
C. tropicalis (2) 353,55 >500 >500 >500 >500 >500 >500 >500 >500 >500 >64 >64
C. lusitaniae (1) 16 125 64 64 125 125 125 125 64 64 0,5 0,5
C. glabrata (1) 250 >500 >500 >500 >500 >500 >500 >500 >500 >500 0,13 0,13
Data are expressed as GM in µg/ml.
TABLE 3 | Antifungal activity of H. hircinum subsp. majus.
Species (strain no.) Methanol Ethanol 80% Infusion Fluconazole
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
C. albicans (4) 31,81 ≥149,5 75,21 >420,4 63,25 >250 4 ≥9,5
C. tropicalis (2) 353,55 >500 353,55 >500 177 >500 >64 >64
C. parapsilosis (5) 53,5 ≥250 250 ≥500 95,18 ≥300 ≥60 >64
C. lusitaniae (2) 16 89,4 63,25 250 32 177 0,35 1,5
C. glabrata (1) 16 64 64 250 64 250 0,13 1
Aspergillus glaucus (1) >500 >500 >500 >500 250 >500 0,25 16
Penicillium paneum (1) >500 >500 >500 >500 64 500 0,13 4
Data are expressed as GM in µg/ml.
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Antifungal Activity of H. hircinum subsp.
majus Extracts
The antifungal activity of H. hircinum subsp. majus was further
investigated against a broader panel of Candida, including
fluconazole resistant strains, and other fungi (Table 3 and
Supplementary Table S3). In addition to crude methanolic
extract, infusion and hydroalcoholic extracts have been tested.
Notably, all H. hircinum subsp. majus extracts showed antifungal
properties and, in particular a remarkable activity against
fluconazole resistant C. parapsilosis and C. tropicalis strains.
The methanolic extract showed the most pronounced cytotoxic
properties. Yet, in general the antifungal activity of the infusion
outcompeted those of the hydroalcoholic extract, also with
respect to the MIC90 values.
Cytotoxicity of H. hircinum subsp. majus
Extracts
The cytototoxicity ofH. hircinum subsp.majus extracts was tested
on PBMC and human skin fibroblast Hs27 cell lines by using
the WST-8 conversion assay. The extracts were tested at a dose
of 500 µg/ml, which corresponds to a 1- (for C. tropicalis) to
10-fold higher concentration than those showing inhibition of
50% of Candida growth. As shown in Figure 1, only the plant
infusion showed no cytotoxic effect on both human cell lines,
while treatment with methanolic and hydroalcoholic extracts
inhibited cell viability by 50% for Hs27 cell line and by 65–70%
for PBMCs.
The effect of H. hircinum subsp. majus on human cells was also
observed microscopically (Figure 2). The imagines confirmed the
cytotoxicity data. Fibroblast treated with plant infusion showed
a normal phenotype, while under treatment with methanolic
and hydro-alcoholic extracts the cell morphology was markedly
altered. The same alteration was observed for PBMCs (data not
shown).
Chemical Composition of H. hircinum
susbps. majus Infusion
The chemical composition of the aqueous extract of H. hircinum
subsp. majus is reported in Table 4. The analysis revealed that
the infusion process allowed the extraction of higher amounts
of phenols in comparison to the extraction by maceration
in methanol. The aqueous extract was mainly characterized
by derivatives of quercetin (24,18 mg/g), of chlorogenic acid
(4,51 mg/g) and by flavan-3-ols (2,26 mg/g). Hyperoside was
the most abundant compound, representing the 2,23% of the
extract. Abundant were also quercetin-3-glucoside (1,65 mg/g),
neochlorogenic acid (2,61 mg/g), chlorogenic acid (1,68 mg/g),
procyanidin B2 (0,89 mg/g), epicatechin (0,59 mg/g) and
procyanidin B1(0,40 mg/g).
DISCUSSION
Plant-based treatments of the traditional medicine could bring
forth new solutions for antifungal therapies. In particular
polyphenol-rich plants represent an import source of bioactive
products for human health (Marchelak et al., 2017) including
antifungal treatments. Among polyphenols, flavan-3-ols,
flavonols and tannins show a high antimicrobial potential
(Daglia, 2012). Flavan-3-ols isolated from green and black tea
exert important anti-Candida activity (Hirasawa and Takada,
2004; Sitheeque et al., 2009), ellagitannins obtained from Punica
granatum inhibit the growth of plant pathogenic fungi (Glazer
et al., 2012), the flavonols myricitrin and fisetin are considered
effective agents against Candida glabrata and Cryptococcus
neoformans, respectively (Salazar-Aranda et al., 2015; Reis et al.,
2016). The mechanisms of action of phenols against Candida
have been intensively studied and include inactivation of
enzyme production (Evensen and Braun, 2009) and anti-biofilm
effects (Evensen and Braun, 2009; Shahzad et al., 2014). Species
FIGURE 1 | Cytotoxicity of H. hircinum subsp. majus extracts (measured
using the WST-8 conversion assay). The metabolic activity is given as the
endpoint of toxicity in human peripheral mononucleate cells (PBMC) and
human skin fibroblast cell line (Hs27), following 24 h exposure to H. hircinum
subsp. majus extracts. Values represent standard error of the mean (n = 3);
Asterisks denote statistically significant differences from control (∗p < 0.05
and ∗∗p < 0.01).
FIGURE 2 | Morphology change of normal fibroblast Hs27 after 24 h
treatment with H. hircinum subsp. majus extracts (observed under inverted
microscope, magnification 100×): (A) control (DMSO), (B) methanolic extract,
(C) hydroalcoholic extract, and (D) infusion.
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belonging to the Hypericum genus are able to synthesize a broad
array of such bioactive phenolic compounds, mainly as products
of the polyketide metabolism (Tocci et al., 2018b), and therefore
might contain novel antifungal remedies.
Here we report new data on the inhibitory activity of extracts
deriving from H. montanum, H. maculatum, H. hirsutum,
and H. hircinum subsp. majus and additional data on the
activity of H. perforatum on the growth of clinical isolates of
Candida spp. The crude extracts obtained from H. maculatum,
H. montanum, H. hirsutum, and H. perforatum showed a
moderate antifungal activity against C. albicans, in the range
of 250–500 µg/ml, good activity against C. lusitaniae (64–
125 µg/ml) and no or only weak activity against C. parapsilosis,
C. tropicalis and C. glabrata. Our data are in accordance
with those of Radulovic´ et al., 2007, showing that extracts
of H. hirsutum, H. maculatum, and H. perforatum exerted
comparable antifungal activity against C. albicans using the
disk diffusion method assay. Discordant data are reported
in Cecchini et al., 2007 which found no activity of extracts
obtained from H. hirsutum or H. montanum against C. albicans.
Most interesting, the antifungal screening of crude extracts
unveiled the promising anti-Candida properties of H. hircinum
subsp. majus. The test showed that extracts obtained from
this species are able to inhibit 50% of growth of C. albicans
at concentrations that are fourfold to eightfold lower than
other Hypericum extracts and with a more pronounced activity
against C. parapsilosis and C. lusitaniae. Moreover H. hircinum
methanolic extract was the only treatment able to inhibit the
growth of C. tropicalis and C. glabrata. These results are
important especially in the light of the increasing incidence
of infections caused by emerging Candida pathogens like
C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei, which
are less susceptible to the commonly used antifungal drugs
(Tortorano et al., 2006; Papon et al., 2013). Previous data on
the antifungal activity of H. hircinum are scarce and limited
to susceptibility tests against just a single reference strain
of C. albicans. Using the disk diffusion test method Pistelli
et al., 2000 found no antifungal activity against the tested
strain, while Cecchini et al., 2007 reported a higher activity of
H. hircinum subsp. majus in comparison to other Hypericum
species.
From a chemical point of view, the extracts applied as
treatments in our tests have been deeply characterized by
investigating the presence of 52 phenolic compounds. In
general, the most abundant classes of detected compounds
were flavonols, benzoate and cinnamates (chlorogenic acid
and neochlorogenic acid), and flavan-3-ols. The major
metabolite in all the extracts was the flavonol hyperoside,
ranging from 4940 ± 66,3 µg/g in H. montanum to
9306 ± 385 µg/g in H. hircinum subsp. majus, and very
abundant were the neochlorogenic acid and the flavan-3-ol
epicatechin. Hyperoside is known for its anticancer, anti-
inflammatory and antimicrobial properties (Ogawa et al.,
2014). The extract of H. hircinum subsp. majus, showed
several chemical peculiarities. It contained the highest
amount of hyperoside, higher amounts of chlorogenic
acid, quercetin-3-glucuronide, kampferol-3-glucuronide,
catechin, epigallogatechin, gallocatechin, and no traces of
the phloroglucinol hyperforin and of the naphtodianthrone
hypericin.
In the light of its pronounced growth inhibition properties
against Candida spp. and considering the ethnobotanical
knowledge available for this species, H. hircinum subsp. majus
has been further subjected to a deeper antifungal screen.
TABLE 4 | Analysis of phenolic compounds in the infusion of H. hircinum subsp. majus.
Compound Amount (µg/g extract) Compound Amount (µg/g extract)
2,6-di-OH-benzoic acid nd∗∗ Kaempferol 1,08 ± 0,15
3,5-dihydroxybenzoic acid 7,08 ± 0,79 Kaempferol -3-glucoside 7,89 ± 1,09
Caffeic acid 44,62 ± 4,97 Kaempferol-3-glucuronide 104,41 ± 14,49
Coniferyl alcohol nd∗ Iso-rhamnetin 0,78 ± 0,11
Gallic acid 15,74 ± 2,18 Iso-rhamnetine-3-glucoside nd∗
Cinnamic acid 6,10 ± 0,85 Syringetin-3-glucoside 3,39 ± 0,46
p-coumaric acid nd∗ Myricetin 7,68 ± 1,07
p-OH-benzoic acid 8,97 ± 1,24 Luteolin 3,51 ± 0,22
Vanillic acid 1,29 ± 0,18 Luteolin 7-O-glucoside 1,77 ± 0,24
Cryptochlorogenic acid 229,7 ± 31,88 Naringenin nd∗
Chlorogenic acid 1683 ± 233,7 Esculin 21,28 ± 2,95
Neochlorogenic acid 2615 ± 362,9 Phlorizin 6,57 ± 0,91
Hyperoside 22203 ± 380 Catechin 282,2 ± 2,71
Quercetin 164,38 ± 15,52 Epicatechin 586,51 ± 68,05
Quercetin-3-arabinoside nd∗ Epigallocatechin 55,77 ± 7,74
Quercetin-3-glucoside 1647 ± 65,03 Gallocatechin 48,92 ± 9,72
Quercetin-3-glucuronide 104,41 ± 14,92 Procyanidin B1 401,6 ± 55,74
Quercetin-3-sulfate nd∗ Procyanidin B2 886,16 ± 108,77
Rutin nd∗ cis-piceid 1,37 ± 0,19
Data are means of three independent experiments, ∗nd, not detected.
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H. hircinum is a shrub native to the areas of the Mediterranean
Basin comprising Greece and Turkey (Euro+Med, 2006).
The infusion of its aerial part is applied in the traditional
medicine to treat chronic catarrhal affections, asthma, sore
throats and cough (Pieroni et al., 2004). Recent scientific
evidences indicate that fungi of the phyla Basidiomycetes
and Ascomycetes (e.g., Bjerkandera, Aspergillus, Candida, and
Saccharomyces) are causative agents of these pathologies (Raza
et al., 2017).
To investigate whether the beneficial effect of H. hircinum
treatments may be attributed to its antifungal activity, we studied,
for the first time, the activity of extracts obtained from the
aerial parts of the plant with a hydroalcoholic solution and,
in accordance with the traditional preparations, by infusion
in boiling water. Additionally, we characterized the chemical
profile. The assay was performed on a broad panel of clinical
Candida strains, a strain of Aspergillus glaucus and a strain
of Penicillium paneum (Table 3 and Supplementary Table S3).
The extract obtained from the herbal tea inhibited 50% of
the growth of all tested fungi, showing strong activity against
both fluconazole sensitive and resistant Candida strains and
moderate activity against Aspergillus and Penicillium strains.
The chemical profile revealed an enrichment in the polyphenol
content in comparison with the crude methanolic extract.
Particularly abundant (content higher than 40 µg/g extract) were
caffeic acid, chlorogenic, neochlorogenic and cryptochlorogenic
acid, quercetin, quercetin-3-glucoside, quercetin-3-glucuronide,
kaempferol-3-glucuronide, all the flavan-3-ols investigated and
extraordinary high levels of hyperoside were detected. Even
if the bioactivity may be due to the synergistic action of
the phytocomplex, it appears reasonable to exclude caffeic
acid, chlorogenic acid, quercetin-3-glucuronide, kaempferol-3-
glucuronide, and gallocatechin as secondary metabolites to
which the antifungal activity may be attributed, since these
compounds are not present in the other Hypericum extracts
showing growth inhibitory properties on Candida strains.
Also, cryptochlorogenic acid, neochlorogenic acid quercetin,
quercetin-3-glucoside, epicatechin, have been detected in all
the crude extract, but they were less present in H. hircinum
subsp. majus and thus their presence cannot be considered
correlated to the bioactivity. According to our data a positive
correlation between the amount of catechin, epigallocatechin,
procyanidin B1 and hyperoside and the antifungal activity exerted
can be individuated. The anti-Candida properties of flavan-3-
ols, and in particular of catechin and epigallocatechin, are well
known and documented (Hirasawa and Takada, 2004; Saito
et al., 2013). Nevertheless, our data suggest that the hyperoside,
being detected in such high amounts in the extract obtained by
the infusion of H. hircinum subsp. majus in water, may play
a fundamental role in the observed fungal growth inhibition
properties. The hypothesis is supported by studies proposing
hyperoside as a lead for the development of new fungicides (Li
et al., 2005).
Finally, the aqueous extract of H. hircinum subsp. majus
showed another promising characteristic exploitable for the
development of a new antifungal therapy. When tested at high
concentrations on human PBMCs and human skin fibroblast
Hs27cell lines, no cytotoxicity was detected.
CONCLUSION
Our work reports a comprehensive phenolic profile of five
European Hypericum species, highlighting the presence of
important exploitable bioactive metabolites. The infusion of
H. hircinum subsp. majus used in the popular medicine for the
treatment of respiratory tract affections has been chemically and
biologically investigated for the first time. The chemical analysis
unveiled a new source of the bioactive metabolite hyperoside
that might be involved in the observed bioactivity of the extract.
The biological tests suggest that the beneficial effects of the
traditional remedies based on H. hircinum could be attributed to
its antiseptic, and in particular to its antifungal properties against
fungal pathogens of the respiratory tract. Moreover, the lack of
cytotoxicity indicates the presence of exploitable and promising
antimycotic principles for the development of an antifungal
therapy with limited cytotoxic side effects. Hence it encourages
future studies to assess the effective therapeutic properties of
H. hircinum subsp. majus with particular attention to the
treatment of fungal-associated pathologies of the respiratory
tract.
ETHICS STATEMENT
PBMCs were obtained from buffy coats prepared from blood
donations collected at the Centro Trasfusionale c/o Ospedale
Santa Chiara, Trento, after donor’s signed informed consent.
Study procedures were approved by the Comitato Etico per
le Sperimentazioni Cliniche, Azienda Provinciale per i Servizi
Sanitari di Trento on the 12th February 2015.
AUTHOR CONTRIBUTIONS
NT, TW, and FM conceived the study and wrote the manuscript
with contributions from all authors. NT, DP, FF, and TW
performed the experiments. DI identified the species. NT, DP, and
TW analyzed the data. NT drafted the manuscript. All authors
approved the final manuscript.
FUNDING
This work was supported by the Project ADP 2016, funded by the
Autonomous Province of Trento, Italy.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fphar.2018.
00382/full#supplementary-material
Frontiers in Pharmacology | www.frontiersin.org 8 April 2018 | Volume 9 | Article 382
fphar-09-00382 April 20, 2018 Time: 12:10 # 9
Tocci et al. Antimycotic Hypericum Herbal Extracts
REFERENCES
Abreu, A. C., McBain, A. J., and Simões, M. (2012). Plants as sources of new
antimicrobials and resistance-modifying agents. Nat. Prod. Rep. 29, 1007–1021.
doi: 10.1039/c2np20035j
Arif, T., Bhosale, J. D., Kumar, N., Mandal, T. K., Bendre, R. S., Lavekar, G. S., et al.
(2009). Natural products–antifungal agents derived from plants. J. Asian Nat.
Prod. Res. 11, 621–638. doi: 10.1080/10286020902942350
Arsic, I., Žugic, A., Antic, D. R., Zdunic, G., Dekanski, D., Markovic, G., et al.
(2010). Hypericum perforatum L. Hypericaceae/Guttiferae sunflower, olive and
palm oil extracts attenuate cold restraint stress - induced gastric lesions.
Molecules 15, 6688–6698. doi: 10.3390/molecules15106688
Atanasov, A. G., Waltenberger, B., Eva-Maria Pferschy-Wenzig, T. L.,
Wawrosch, C., Uhrin, P., Temml, V., et al. (2016). Discovery and resupply of
pharmacologically active plant- derived natural products: a review. Biotechnol.
Adv. 33, 1582–1614. doi: 10.1016/j.biotechadv.2015.08.001.Discovery
Ayan, A. K., Kizilkaya, R., Cirak, C., and Kevseroglu, K. (2006). Heavy metal
contents of St. John’s wort (Hypericum perforatum L.) Growing in Northern
Turkey. J. Plant Sci. 1, 182–186. doi: 10.3923/jps.2006.182.186
Barros, F. M., Pippi, B., Dresch, R. R., Dauber, B., Luciano, S. C., Apel, M. A., et al.
(2013). Antifungal and antichemotactic activities and quantification of phenolic
compounds in lipophilic extracts of Hypericum spp. native to South Brazil. Ind.
Crops Prod. 44, 294–299. doi: 10.1016/j.indcrop.2012.11.017
Bartolucci, F., Peruzzi, L., Galasso, G., Albano, A., Alessandrini, A., Ardenghi,
N. M. G., et al. (2018). An updated checklist of the vascular flora native to Italy.
Plant Biosyst. 152, 179–303. doi: 10.1080/11263504.2017.1419996
Borgers, M., Degreef, H., and Cauwenbergh, G. (2005). Fungal infections of the
skin: infection process and antimycotic therapy. Curr. Drug Targets 6, 849–862.
doi: 10.2174/138945005774912726
Brown, G. D., Denning, D. W., Gow, N. A., Levitz, S. M., Netea, M. G., and
White, T. C. (2012). Hidden killers: human fungal infections. Sci. Transl. Med.
4:165rv13. doi: 10.1126/scitranslmed.3004404
Cecchini, C., Cresci, A., Coman, M. M., Ricciutelli, M., Sagratini, G., Vittori, S.,
et al. (2007). Antimicrobial activity of seven Hypericum entities from central
Italy. Planta Med. 73, 564–566.
Crockett, S. L., Poller, B., Tabanca, N., Pferschy-Wenzig, E. M., Kunert, O., Wedge,
D. E., et al. (2011). Bioactive xanthones from the roots of Hypericum perforatum
(common St John’s wort). J. Sci. Food Agric. 91, 428–434. doi: 10.1002/jsfa.4202
Daglia, M. (2012). Polyphenols as antimicrobial agents. Curr. Opin. Biotechnol. 23,
174–181. doi: 10.1016/j.copbio.2011.08.007
Dismukes, W. E. (2000). Introduction to antifungal drugs. Clin. Inf. Dis. 30,
653–657. doi: 10.1086/313748
Dugoua, J.-J., Mills, E., Perri, D., and Koren, G. (2006). Safety and efficacy of
St. John’s wort (hypericum) during pregnancy and lactation. Can. J. Clin.
Pharmacol. 13, e268–76.
Euro+Med (2006). Euro+Med Plant Base the Information Resource for
Euro-Mediterranean Plant Diversity. Available at: http://ww2.bgbm.org/
EuroPlusMed/ [accessed December 15, 2017].
European Committee for Antimicrobial Susceptibility Testing (2012). Method for
the Determination of Broth Dilution Minimum Inhibitory Concentrations of
Antifungal Agents for Yeasts. EUCAST DEFINITIVE DOCUMENT EDef 7. 2
Revision. Brussels: European Commission.
Evensen, N. A., and Braun, P. C. (2009). The effects of tea polyphenols on Candida
albicans: inhibition of biofilm formation and proteasome inactivation. Can. J.
Microbiol. 55, 1033–1039. doi: 10.1139/w09-058
Glazer, I., Masaphy, S., Marciano, P., Bar-Ilan, I., Holland, D., Kerem, Z., et al.
(2012). Partial identification of antifungal compounds from Punica granatum
peel extracts. J. Agric. Food Chem. 60, 4841–4848. doi: 10.1021/jf300330y
Gurib-Fakim, A. (2006). Medicinal plants: traditions of yesterday and drugs of
tomorrow. Mol. Aspects Med. 27, 1–93. doi: 10.1016/j.mam.2005.07.008
Hirasawa, M., and Takada, K. (2004). Multiple effects of green tea catechin on
the antifungal activity of antimycotics against Candida albicans. J. Antimicrob.
Chem. 53, 225–229. doi: 10.1093/jac/dkh046
Johnson, D. C. (2012). Chronic candidal bronchitis: a consecutive series. Open
Respir. Med. J. 6, 145–149. doi: 10.2174/1874306401206010145
Lass-Flörl, C. (2009). The changing face of epidemiology of invasive fungal
disease in Europe. Mycoses 52, 197–205. doi: 10.1111/j.1439-0507.2009.
01691.x
Li, S., Zhang, Z., Cain, A., Wang, B., Long, M., and Taylor, J. (2005). Antifungal
activity of camptothecin, trifolin, and hyperoside isolated from Camptotheca
acuminata. J. Agric. Food Chem. 53, 32–37. doi: 10.1021/jf0484780
Marchelak, A., Owczarek, A., Matczak, M., Pawlak, A., Kolodziejczyk-Czepas, J.,
Nowak, P., et al. (2017). Bioactivity potential of Prunus spinosa L. Flower
extracts: phytochemical profiling, cellular safety, pro-inflammatory enzymes
inhibition and protective effects against oxidative stress in vitro. Front.
Pharmacol. 8:680. doi: 10.3389/fphar.2017.00680
Menkovic, N., Savikin, K., Tasic, S., Zdunic, G., Stesevic, D., Milosavljevic, S.,
et al. (2011). Ethnobotanical study on traditional uses of wild medicinal
plants in Prokletije Mountains (Montenegro). J. Ethnopharmacol. 133, 97–107.
doi: 10.1016/j.jep.2010.09.008
Nürk, N. M., and Crockett, S. L. (2011). Morphological and phytochemical
diversity among Hypericum species of the Mediterranean Basin. Med. Aromat.
Plant Sci. Biotechnol. 5, 14–28.
Ogawa, H., Fujimura, M., Ohkura, N., and Makimura, K. (2014). It is
time to call attention to the clinical significance of fungal colonization
in chronic cough. Allergol. Int. 63, 611–612. doi: 10.2332/allergolint.
14-LE-0691
Papon, N., Courdavault, V., Clastre, M., and Bennett, R. J. (2013). Emerging and
emerged pathogenic candida species: beyond the Candida albicans paradigm.
PLoS Pathog. 9:e1003550. doi: 10.1371/journal.ppat.1003550
Pieroni, A., Quave, C. L., and Santoro, R. F. (2004). Folk pharmaceutical
knowledge in the territory of the Dolomiti Lucane, inland southern Italy.
J. Ethnopharmacol. 95, 373–384. doi: 10.1016/j.jep.2004.08.012
Pignatti, S. (1982). Flora d’Italia. Bologna: Edagricole.
Pignatti, S. (2017). Flora d’Italia, 2nd Edn. Bologna: Edagricole.
Pistelli, L., Bertoli, A., Zucconelli, S., Morelli, I., Panizzi, L., and Menichini, F.
(2000). Antimicrobial activity of crude extracts and pure compounds of
Hypericum hircinum. Fitoterapia 71, S138–S140. doi: 10.1016/S0367-326X(00)
00189-1
Raclariu, A. C., Paltinean, R., Vlase, L., Labarre, A., Manzanilla, V., Ichim, M. C.,
et al. (2017). Comparative authentication of Hypericum perforatum herbal
products using DNA metabarcoding, TLC and HPLC-MS. Sci. Rep. 7:1291.
doi: 10.1038/s41598-017-01389-w
Radulovic´, N., Stankov-Jovanovic´, V., Stojanovic´, G., Šmelcerovic´, A., Spiteller, M.,
and Asakawa, Y. (2007). Screening of in vitro antimicrobial and antioxidant
activity of nine Hypericum species from the Balkans. Food Chem. 103, 15–21.
doi: 10.1016/j.foodchem.2006.05.062
Raza, A., Xu, X., Sun, H., Tang, J., and Ouyang, Z. (2017). Pharmacological activities
and pharmacokinetic study of hyperoside: a short review. Trop. J. Pharm. Res.
16, 483–489. doi: 10.4314/tjpr.v16i2.30
Reis, M. P. C., Carvalho, C. R. C., Andrade, F. A., Fernandes, O. D. F. L.,
Arruda, W., and Silva, M. R. R. (2016). Fisetin as a promising antifungal
agent against Cryptococcus neoformans species complex. J. Appl. Microbiol. 121,
373–379. doi: 10.1111/jam.13155
Ritchie, T., and Eltahawy, E. (2014). Diagnosis and management of fungal urinary
tract infections. Curr. Bladder Dysfunct. Rep. 9, 161–166. doi: 10.1007/s11884-
014-0238-7
Sagratini, G., Ricciutelli, M., Vittori, S., Öztürk, N., Öztürk, Y., and Maggi, F.
(2008). Phytochemical and antioxidant analysis of eight Hypericum taxa from
Central Italy. Fitoterapia 79, 210–213. doi: 10.1016/j.fitote.2007.11.011
Saito, H., Tamura, M., Imai, K., Ishigami, T., and Ochiai, K. (2013). Catechin
inhibits Candida albicans dimorphism by disrupting Cek1 phosphorylation
and cAMP synthesis. Microb. Pathog. 56, 16–20. doi: 10.1016/j.micpath.2013.
01.002
Salazar-Aranda, R., Granados-Guzmán, G., Pérez-Meseguer, J., González, G. M.,
and de Torres, N. W. (2015). Activity of polyphenolic compounds
against Candida glabrata. Molecules 20, 17903–17912. doi: 10.3390/molecules
201017903
Saric´-Kundalic´, B., Dobes, C., Klatte-Asselmeyer, V., and Saukel, J. (2010).
Ethnobotanical study on medicinal use of wild and cultivated plants in middle,
south and west Bosnia and Herzegovina. J. Ethnopharmacol. 131, 33–55.
doi: 10.1016/j.jep.2010.05.061
Shahzad, M., Sherry, L., Rajendran, R., Edwards, C. A., Combet, E., and
Ramage, G. (2014). Inhibitory effect of plant (poly) phenolics on growth and
biofilm formation by Candida albicans. Proc. Nutr. Soc. 73:E28. doi: 10.1017/
S0029665114000421
Frontiers in Pharmacology | www.frontiersin.org 9 April 2018 | Volume 9 | Article 382
fphar-09-00382 April 20, 2018 Time: 12:10 # 10
Tocci et al. Antimycotic Hypericum Herbal Extracts
Sitheeque, M. A. M., Panagoda, G. J., Yau, J., Amarakoon, A. M. T., Udagama,
U. R. N., and Samaranayake, L. P. (2009). Antifungal activity of black tea
polyphenols (catechins and theaflavins) against Candida species. Chemotherapy
55, 189–196. doi: 10.1159/000216836
Stojanovic, G., Dordevic, A., and Smelcerovic, A. (2013). Do other Hypericum
species have medical potential as St. John’s Wort (Hypericum perforatum)?Curr.
Med. Chem. 20, 2273–2295. doi: 10.2174/0929867311320180001
Strati, F., Di Paola, M., Stefanini, I., Albanese, D., Rizzetto, L., Lionetti, P., et al.
(2016). Age and gender affect the composition of fungal population of the
human gastrointestinal tract. Front. Microbiol. 7:1277. doi: 10.3389/fmicb.2016.
01227
Tocci, N., Gaid, M., Kaftan, F., Belkheir, A. K., Belhadj, I., Liu, B., et al.
(2018b). Exodermis and endodermis are the sites of xanthone biosynthesis in
Hypericum perforatum roots. New Phytol. 217, 1099–1112. doi: 10.1111/nph.
14929
Tocci, N., Weil, T., Perenzoni, D., Narduzzi, L., Madriñán, S., Crockett, S.,
et al. (2018a). Phenolic profile, chemical relationship and antifungal activity of
Andean Hypericum species. Ind. Crops Prod. 112, 32–37. doi: 10.1016/j.indcrop.
2017.10.030
Tocci, N., Simonetti, G., D’Auria, F. D., Panella, S., Palamara, A. T., Ferrari, F.,
et al. (2013). Chemical composition and antifungal activity of Hypericum
perforatum subsp. angustifolium roots from wild plants and plants grown under
controlled conditions. Plant Biosyst. 147, 557–562. doi: 10.1080/11263504.2013.
806964
Tortorano, A. M., Kibbler, C., Peman, J., Bernhardt, H., Klingspor, L., and
Grillot, R. (2006). Candidaemia in Europe: epidemiology and resistance.
Int. J. Antimicrob. Agents 27, 359–366. doi: 10.1016/j.ijantimicag.2006.
01.002
Vrhovsek, U., Masuero, D., Gasperotti, M., Franceschi, P., Caputi, L., Viola, R., et al.
(2012). A versatile targeted metabolomics method for the rapid quantification
of multiple classes of phenolics in fruits and beverages. J. Agric. Food Chem. 60,
8831–8840. doi: 10.1021/jf2051569
Weil, T., Santamaría, R., Lee, W., Rung, J., Tocci, N., Abbey, D., et al. (2017).
Adaptive mistranslation accelerates the evolution of fluconazole resistance and
induces major genomic and gene expression alterations in Candida albicans.
mSphere 2, e00167–17.
World Health Organization [WHO] (2014).Antimicrobial Resistance Global Report
on Surveillance 2014. Geneva: WHO Press.
Zager, R. A. (2000). Polyene antibiotics: relative degrees of in vitro cytotoxicity and
potential effects on tubule phospholipid and ceramide content. Am. J. Kidney
Dis. 36, 238–249. doi: 10.1053/ajkd.2000.8967
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer LA declared a shared affiliation, though no other collaboration, with
one of the authors DI to the handling Editor.
Copyright © 2018 Tocci, Perenzoni, Iamonico, Fava, Weil and Mattivi. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pharmacology | www.frontiersin.org 10 April 2018 | Volume 9 | Article 382
